Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Discriminating phenotypic signatures identified for tocilizumab, adalimumab, and tofacitinib monotherapy and their combinations with methotrexate.

Journal of translational medicine - 7 Jun 2018

O'Mahony Alison, John Markus R, Cho Hannah, Hashizume Misato, Choy Ernest H

Abstract excerpt

BACKGROUND: Clinical trials have shown combinations of anti-tumor necrosis factor biologicals plus methotrexate (MTX) are more effective treatments for rheumatoid arthritis than biological monotherapies, based, in part, on the assumption that MTX reduces the immunogenicity of biologicals. However, co-treatment with the anti-interleukin-6 receptor-alpha antibody tocilizumab (TCZ) and MTX does not demonstrate the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adalimumab
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Arthritis, Rheumatoid

Share to Methotrexate

Share to Piperidines

Share to Pyrimidines

Share to Pyrroles

Share to Receptors, Interleukin-6

Source

Open in PubMed Open full text

Identifiers

PMID: 29879987
DOI: 10.1186/s12967-018-1532-5
PMCID: PMC5992722

Genes

ADA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Discriminating phenotypic signatures identified for tocilizumab, adalimumab, and tofacitinib monotherapy and their combinations with methotrexate.PMID 29879987Read ↗

Differences and Similarities in Clinical and Functional Responses Among Patients Receiving Tofacitinib Monotherapy, Tofacitinib Plus Methotrexate, and Adalimumab Plus Methotrexate: A Post-hoc Analysis of Data From Oral StrategySemantic proximity Read ↗

Combination antagonism of TNF superfamily signaling for T cell immunosuppressionSemantic proximity Read ↗

Can rheumatoid arthritis responsiveness to methotrexate and biologics be predicted?Semantic proximity Read ↗

Predictive factors of response to biological disease modifying antirheumatic drugs: towards personalized medicine.Semantic proximity Read ↗

A Cell-Based Reporter Gene Assay for TNF-α Neutralization: Analytical Qualification and Application to Adalimumab and Its BiosimilarsSemantic proximity Read ↗

Using the Immunophenotype to Predict Response to Biologic Drugs in Rheumatoid ArthritisSemantic proximity Read ↗

The Oncology: Disease Modifying Anti-Rheumatic Drug Interface: A Cross-Specialty ReviewSemantic proximity Read ↗

Transcriptome-wide study of TNF-inhibitor therapy in rheumatoid arthritis reveals early signature of successful treatmentSemantic proximity Read ↗

Safety outcomes in patients with rheumatoid arthritis treated with abatacept: results from a multinational surveillance study across seven European registriesSemantic proximity Read ↗

Prediction of Therapeutic Responses to Tocilizumab in Patients With Rheumatoid Arthritis: Biomarkers Identified by Analysis of Gene Expression in Peripheral Blood Mononuclear Cells Using Genome‐Wide DNA MicroarraySemantic proximity Read ↗

Add-on Iguratimod or Tacrolimus in Methotrexate Inadequate Rheumatoid Arthritis: Efficacy, Safety and Propensity Score-Matched AnalysisSemantic proximity Read ↗

Phenotypic response surfaces in pharmacology: Mechanistic and translational perspectives on optimizing drug combination therapies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.